



More pharma companies mull Para IV challengesPosted AtThe Financial ExpressIt's not just Ranbaxy and Dr Reddy's
Laboratories (DRL) who have decided to challenge blockbuster
drugs from MNCs. In a significant move, it is learnt
that five Indian pharma companies - Cipla, Wockhardt,
Orchid, Matrix Labs and Aurobindo Pharma - are evaluating
the option of Para IV filing of their abbreviated new
drug application (ANDA) in the US and Europe. These
companies are in talks with patent lawyers and consultants
for Para IV filing, according to industry sources.These
companies are targeting drugs valued at $300-$600 million
and will go for para IV filing either alone, or jointly
with other companies since the process is expensive,
sources added. Sources also said that Cipla may tie
up with one of its associates in the US for Para IV
filing, since it may not want to directly come under
the litigation procedures. October 24, 2005
|